Simvastatin and lovastatin, but not pravastatin, interact with MDR1

• Published in: Journal of pharmacy and pharmacology Vol. 54; no. 3; p. 419
• Main Authors: Sakaeda, Toshiyuki, Takara, Kohji, Kakumoto, Mikio, Ohmoto, Nobuko, Nakamura, Tsutomu, Iwaki, Koichi, Tanigawara, Yusuke, Okumura, Katsuhiko
• Format: Journal Article
• Language: English
• Published: England 01.03.2002
• Subjects: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1 - drug effects; Biological Transport - drug effects; Cells, Cultured; Digoxin - metabolism; Drug Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Lovastatin - pharmacology; Pravastatin - pharmacology; Simvastatin - pharmacology; Swine
• ISSN: 0022-3573
• DOI: 10.1211/0022357021778493

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, pravastatin, was compared with simvastatin and lovastatin from the viewpoint of susceptibility to interaction with or via the multidrug transporter, MDR1 (P-glycoprotein). This was carried out using the MDR1-overexpressing cell line LLC-GA5-COL150, established by transfection of MDR1 cDNA into porcine kidney epithelial LLC-PK1 cells, and [3H]digoxin, which is a well-documented substrate for MDR1. Pravastatin, at 25-100 microM, had no effect on the transcellular transport of [3H]digoxin whereas simvastatin and lovastatin suppressed the basal-to-apical transport of [3H]digoxin and increased the apical-to-basal transport. It was suggested that recognition by MDR1 was due to the hydrophobicity. In conclusion, simvastatin and lovastatin are susceptible to interaction with or via MDR1, but pravastatin is not. This is important information when selecting the HMG-CoA reductase inhibitors for patients taking drugs that are MDR1 substrates.